Here are the top 10 most valuable projects in the pipeline — ranked by their net present value — as well as their estimated worldwide product sales in 2026:
- Tirzepatide (Eli Lilly) — $2.2 billion
- Inclisiran (Novartis) — $2 billion
- Efgartigimod (argenx) — $2 billion
- BMS-986165 (Bristol-Myers Squibb) — $1.8 billion
- ALN-HBV02 (Vir Biotechnology) — $1.2 billion
- Aducanumab (Biogen) — $1.6 billion
- Belantamab (GlaxoSmithKline) — $1.3 billion
- LN-144 (Iovance Biotherapeutics) — $1.5 billion
- AK002 (Allakos) — $1.2 billion
- Risdiplam (Roche) — $1.4 billion
More articles on pharmacy:
NIH updates remdesivir treatment guidelines
J&J to start human trials for COVID-19 vaccine this week
CVS fined for understaffing, prescription errors in Oklahoma
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
